JP2004217610A - Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water - Google Patents

Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water Download PDF

Info

Publication number
JP2004217610A
JP2004217610A JP2003040375A JP2003040375A JP2004217610A JP 2004217610 A JP2004217610 A JP 2004217610A JP 2003040375 A JP2003040375 A JP 2003040375A JP 2003040375 A JP2003040375 A JP 2003040375A JP 2004217610 A JP2004217610 A JP 2004217610A
Authority
JP
Japan
Prior art keywords
deuterium
water
cancer
physiological saline
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003040375A
Other languages
Japanese (ja)
Inventor
Tatsuo Usui
龍夫 臼井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INTERNATL SCIENT KK
International Scientific Co Ltd
Original Assignee
INTERNATL SCIENT KK
International Scientific Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INTERNATL SCIENT KK, International Scientific Co Ltd filed Critical INTERNATL SCIENT KK
Priority to JP2003040375A priority Critical patent/JP2004217610A/en
Publication of JP2004217610A publication Critical patent/JP2004217610A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for infusing a physiological saline containing deuterium-depleted water (super light water) as a raw material into the body by intravenous drip in order to treat cancer, diabetes, leukemia and insomnia and also to promote rejuvenation, cell activation and immunocyte proliferation. <P>SOLUTION: The treatment of cancer, diabetes, leukemia and insomnia, and the promotion of rejuvenation, cell activation and immunocyte proliferation can effectively be performed by the application of deuterium-depleted water (super light water) and the physiological saline containing the deuterium depleted water as a raw material. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は、癌、糖尿病、白血病、不眠症の治療および若返り、細胞の活性化、免疫細胞の増加の促進を行う。重水素減少水(スーパーライトウォーター)を原料とした生理的食塩水を点滴で体内に注入することによっておこなうものである。
【0002】
【従来の技術】
一般に老人になるとメラトニンが出なくなり、眠りが浅く従って睡眠中に作られるNK細胞も少なくなり、癌、糖尿病、白血病、不眠症の治療は外科手術、放射線治療、投薬治療などで対処するのが通常であるが、この場合、当人が病院や診療所に直接行って治療を受ける。
【0003】
また、若返り、細胞の活性化、免疫細胞の増加に効果がある健康食品が多数販売されている昨今において、さまざまな健康食品を入手して体質改善をする対象者が増えている。
【0004】
【発明が解決しようとする課題】
しかしながら現実において、従来の治療や健康食品による体質改善が治療として成果が上がらないことがあり、DNAの複製に失敗した異常細胞は、シミ、血管種であるあざ、いぼ、しわ、老人班、癌、糖尿病の原因となり、ベーター細胞の複製失敗細胞は、体内のあらゆる細胞の複製失敗細胞を作り出す。
【0005】
【課題を解決するための手段】
本発明者等は係る課題を解決するために鋭意研究したところ、癌、糖尿病、白血病、不眠症の治療および若返り、細胞の活性化、免疫細胞の増加の促進のための重水素減少水(スーパーライトウォーター)を原料とした生理的食塩水を開発して、本発明を提供するものである。
【0006】
すなわち本発明は癌、糖尿病、白血病、不眠症の治療および若返り、細胞の活性化、免疫細胞の増加の促進に最適な重水素減少水(スーパーライトウォーター)を飲用や重水素減少水(スーパーライトウォーター)を原料とした生理的食塩水を点滴により体内に注入し、体内の重水素濃度を低下させることを特徴とする癌、糖尿病、白血病、不眠症の治療および若返り、細胞の活性化、免疫細胞の増加の促進方法であり、新陳代謝が活発になるとホルモンの分泌が良くなり、脳内ホルモン(メラトニン)が分泌され深い良質の睡眠が取れる。睡眠によりNK細胞が増加し異常細胞を除去して正常細胞を複製し若返る。
【0007】
【発明の実施の形態】
本発明は重水素減少水(スーパーライトウォーター)を飲用や点滴で体内に注入しより効果的に体内の重水濃度を低下させる。
【0008】
重水素濃度が149ppm以下になるとたんぱく質結合が弱くなり、新陳代謝が高まり分解しやすくなる。結合が弱くなった癌細胞をNK細胞や抗癌剤で壊死させる。
【0009】
新陳代謝が高まることにより若返り、細胞の活性化、免疫細胞の増加の促進のこうかがある。
【0010】
【発明の効果】
以上説明したように、本発明によれば重水素濃度149ppm以下の重水素減少水(スーパーライトウォーター)を飲用や重水素減少水(スーパーライトウォーター)を原料とした生理的食塩水を点滴することにより、体内の重水素濃度を低下させることにより、新陳代謝を高め、結合の弱くなったガン細胞をNK細胞や抗癌剤で壊死させることが可能となる。また、新陳代謝が高まることにより若返り、細胞の活性化、免疫細胞の増加の促進の効果がある。
[0001]
BACKGROUND OF THE INVENTION
The present invention treats and rejuvenates cancer, diabetes, leukemia, and insomnia, promotes cell activation, and increases immune cells. It is performed by injecting physiological saline using deuterium-reduced water (super light water) as a raw material into the body by infusion.
[0002]
[Prior art]
In general, melatonin does not come out when we become old, and sleep is shallow, so NK cell made during sleep decreases, and treatment of cancer, diabetes, leukemia, insomnia is usually treated by surgery, radiation therapy, medication therapy In this case, however, the person goes directly to the hospital or clinic for treatment.
[0003]
In addition, many health foods that are effective in rejuvenating, activating cells, and increasing immune cells are being sold in recent years, and an increasing number of subjects obtain various health foods to improve their constitution.
[0004]
[Problems to be solved by the invention]
However, in reality, the improvement of constitution by conventional treatments and health foods may not be successful as treatment, and abnormal cells that fail to replicate DNA are spots, blood vessels such as bruises, warts, wrinkles, geriatric groups, and cancer. Due to diabetes, beta cell replication failure cells produce replication failure cells of every cell in the body.
[0005]
[Means for Solving the Problems]
The present inventors have conducted intensive research to solve such problems, and have found that deuterium-depleted water (supermarkets) for the promotion of cancer, diabetes, leukemia, insomnia treatment and rejuvenation, cell activation, and immune cell increase. The present invention is provided by developing physiological saline using light water as a raw material.
[0006]
That is, the present invention relates to deuterium-depleted water (superlight water) that is optimal for the treatment and rejuvenation of cancer, diabetes, leukemia, insomnia, cell activation, and increase of immune cells. Physiological saline using water as a raw material is infused into the body by infusion to reduce the deuterium concentration in the body. Treatment and rejuvenation of cancer, diabetes, leukemia, insomnia, cell activation, immunity It is a method of promoting cell growth. When metabolism is activated, hormone secretion is improved, and brain hormone (melatonin) is secreted, resulting in deep sleep. Sleep increases NK cells, removes abnormal cells, replicates normal cells, and rejuvenates.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
In the present invention, deuterium-reduced water (super light water) is injected into the body by drinking or drip, thereby reducing the concentration of heavy water in the body more effectively.
[0008]
When the deuterium concentration is 149 ppm or less, protein binding is weakened, metabolism is increased, and decomposition is likely to occur. Cancer cells that have weakened binding are necrotized with NK cells or anticancer agents.
[0009]
There is a way to promote rejuvenation, cell activation, and increase in immune cells by increasing metabolism.
[0010]
【The invention's effect】
As described above, according to the present invention, deuterium-reduced water (superlight water) having a deuterium concentration of 149 ppm or less is used for drinking or physiological saline using deuterium-reduced water (superlight water) as a raw material. Thus, by reducing the deuterium concentration in the body, it becomes possible to increase metabolism and to necrotize cancer cells that have become weakly bound with NK cells or anticancer agents. In addition, an increase in metabolism has the effect of rejuvenating, activating cells, and promoting an increase in immune cells.

Claims (2)

水と、149ppm以下の含有量の重水素を有し、又は、活性剤として、149ppm以下の含有量の重水素を含み、担体又は助剤と共に、製薬学的な製品或いは医薬溶液の形での、ヒトに適する水性溶液である、重水素減少水(スーパーライトウォーター)を原料とした生理的食塩水による癌、糖尿病、白血病、不眠症の治療および若返り、細胞の活性化、免疫細胞の増加の促進を行う。Having deuterium with a content of 149 ppm or less, or as an active agent with a deuterium content of 149 ppm or less, together with a carrier or auxiliary agent, in the form of a pharmaceutical product or solution , Treatment and rejuvenation of cancer, diabetes, leukemia, insomnia, activation of cells, increase of immune cells by physiological saline using deuterium-reduced water (super light water) as an aqueous solution suitable for humans Promote. 重水素濃度が149ppm以下になるとたんぱく質結合が弱くなり、新陳代謝が高まり分解しやすくなる。重水素減少水(スーパーライトウォーター)を飲用や重水素減少水(スーパーライトウォーター)を原料とした生理的食塩水を点滴することにより、体内の重水素濃度を低下させ新陳代謝を高め、結合の弱くなったガン細胞をNK細胞や抗癌剤で壊死させる。When the deuterium concentration is 149 ppm or less, protein binding is weakened, metabolism is increased, and decomposition is likely to occur. Drinking deuterium-depleted water (super light water) or instilling physiological saline from deuterium-depleted water (super light water) as a raw material reduces the deuterium concentration in the body, increases metabolism, and weakens the bond. The resulting cancer cells are necrotized with NK cells or anticancer agents.
JP2003040375A 2003-01-15 2003-01-15 Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water Pending JP2004217610A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003040375A JP2004217610A (en) 2003-01-15 2003-01-15 Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003040375A JP2004217610A (en) 2003-01-15 2003-01-15 Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water

Publications (1)

Publication Number Publication Date
JP2004217610A true JP2004217610A (en) 2004-08-05

Family

ID=32905221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003040375A Pending JP2004217610A (en) 2003-01-15 2003-01-15 Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water

Country Status (1)

Country Link
JP (1) JP2004217610A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065734A1 (en) * 2006-11-27 2008-06-05 Oct Incorporated Aqueous composition
CN107811968A (en) * 2017-12-14 2018-03-20 官鲁东 The low deuterium-oxide parenteral solution of application and glucose of the low deuterium-oxide in glucose injection
US20190224193A1 (en) * 2013-03-14 2019-07-25 Christopher Brian Reid Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065734A1 (en) * 2006-11-27 2008-06-05 Oct Incorporated Aqueous composition
US20190224193A1 (en) * 2013-03-14 2019-07-25 Christopher Brian Reid Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases
CN107811968A (en) * 2017-12-14 2018-03-20 官鲁东 The low deuterium-oxide parenteral solution of application and glucose of the low deuterium-oxide in glucose injection

Similar Documents

Publication Publication Date Title
PL340096A1 (en) Methods of treating hypercoagulability states or hypoproteinaemia in respect to c protein
CN107670044A (en) Comprising the treatment using magnetic dipole stabilizing solutions or improve disease and strengthen the method for performance
JP2004217610A (en) Treatment of cancer, diabetes, leukemia and insomnia, and promotion of rejuvenation, cell activation and immunocyte proliferation by physiological saline comprizing deuterium-depleted water
US6495585B2 (en) Method for treating hyperproliferative tissue in a mammal
CN103977194A (en) Application of drug for external use capable of effectively treating wound infection in preparing medicaments for treating diabetic foot
Fu et al. Application of dexmedetomidine‐remifentanil in high‐intensity ultrasound ablation of uterine fibroids: a randomised study
Castagna et al. Radio electric tissue optimization in the treatment of surgical wounds
WO2009094811A1 (en) A royal jelly acidic mixture preparation and application thereof
KR20100024019A (en) Multi-purpose food concentrate mineral preparation and preparation method thereof
JP2004277391A (en) Treatment of cancer, diabetes, leukemia and insomnia with sake brewed using deuterium-reduced water and its use for rejuvenation, activation of cells, and acceleration of increase of immunocyte, and production method thereof
CN105816598A (en) Medicine for treating burns and scalds and preparation method thereof
JP2006241129A (en) Method for using tpn(total parenteral nutrition) containing syrup, electrolyte, etc. using superlight water and superlight nutrient
US20160068841A1 (en) Cancer treatment methods using remote conditioning
JP2004315488A (en) Treatment of cancer, diabetes, leukemia and insomnia and rejuvenation, activation of cell and promotion of immunocyte increase by using beer brewed in deuterium-reduced water (super light water) as raw material
KR101130617B1 (en) A funtional drink containing multifuntional mineral complex
JP2004357678A (en) Treatment of cancer, diabetes mellitus, leukemia, aplastic anemia and insomnia, treatment and prevention of severe acute respiratory syndrome (sars), rejuvenation, activation of cell and promotion of increase of immune cell by soy sauce prepared by using deuterium-attrited water (super light water) as raw material, and method for producing the same
RU2676836C2 (en) Device for treatment of immune function deficiency and regulation of metabolism
Reipschläger et al. Combined neodymium-doped yttrium aluminum garnet laser and sclerotherapy in Gorham-Stout syndrome
Land Analysis of the Curative Effect from the Injection of Sclerosing Agent in 1,000 Patients with Vascular Abnormalities
Suzuki et al. Project 4 Clinical research on explorations into new application of BNCT (31P4)
RU2508097C1 (en) Method for multimodality therapy for diabetic foot
Medina Laser therapy and acupuncture
JP2004315490A (en) Therapy for aplastic anemia (myelodysplastic syndrome) with physiological saline solution of deuterium-reduced water (super light water)
Tomar et al. Role of Clonidine in Fascia Iliaca Compartment Block for Preoperative Analgesia in Post Hip Fracture Patients: A Comparative Study
Glass et al. Daily walks can improve digestion, chronic conditions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118